Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 321 to 330 of 999 total matches.

Cevimeline (Evoxac) For Dry Mouth

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Med Lett Drugs Ther. 2000 Aug 7;42(1084):70 |  Show IntroductionHide Introduction

Eflornithine Cream For Facial Hair Reduction

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Eflornithine hydrochloride cream 13.9% (Vaniqa - Bristol-Myers Squibb) has been approved by the FDA for reduction of unwanted facial hair in women.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):96 |  Show IntroductionHide Introduction

Cool.click: A Needle-free Device For Growth Hormone Delivery

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
A new needle-free system (cool.click) has been approved by the FDA for subcutaneous delivery of Saizen (recombinant somatotropin - Serono). Somatotropin is used for long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. Children with growth hormone deficiency require injections daily or several times weekly for many years.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):2-3 |  Show IntroductionHide Introduction

PC Spes

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
PC Spes, a dietary supplement sold for "prostate health", is being used increasingly to treat prostate cancer.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):15-6 |  Show IntroductionHide Introduction

Direct-to-consumer Advertisements For Glucophage XR

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew ...
Full-page newspaper advertisements addressed to patients with type 2 diabetes are promoting the convenience of "NEW once-a-day Glucophage XR (metformin HCl extended-release tablets),"and offering a coupon for a free 30-day supply in the month of March.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):25-6 |  Show IntroductionHide Introduction

Newer Antihistamines

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001  (Issue 1103)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the newer, non-sedating antihistamines.
Med Lett Drugs Ther. 2001 Apr 30;43(1103):35 |  Show IntroductionHide Introduction

GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.
Med Lett Drugs Ther. 2001 May 14;43(1104):42 |  Show IntroductionHide Introduction

Initial Treatment of Parkinson's Disease:Wait Just a Minute

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001  (Issue 1108)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew ...
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):59-60 |  Show IntroductionHide Introduction

Ortho Evra - A Contraceptive Patch

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002  (Issue 1122)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
A transdermal contraceptive patch (Ortho Evra — Ortho-McNeil) has been approved by the FDA. Each 20 cm2 patch contains 6 mg of the progestin norelgestromin (the active metabolite of norgestimate) and 0.75 mg of ethinyl estradiol.
Med Lett Drugs Ther. 2002 Jan 21;44(1122):8 |  Show IntroductionHide Introduction

Anakinra (Kineret) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002  (Issue 1124)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D., Oregon ...
Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one disease-modifying anti-rheumatic drug(DMARD) such as methotrexate (Medical Letter 2000; 24:57).
Med Lett Drugs Ther. 2002 Feb 18;44(1124):18-9 |  Show IntroductionHide Introduction